Immunotherapy harnesses the components of an individual's own immune system to identify and attack cancer cells. One form of immunotherapy is adoptive cell transfer (ACT), where the patient's immune cells are collected, genetically modified, and re-infused. 

CAR-T immunotherapy is one type of ACT that has shown exceptional promise against both blood cancers and solid tumors. CAR-T cells are T cells expressing specialized engineered receptors called chimeric antigen receptors (CARs) which counter tumor evasion by improving recognition specificity for tumor cells and removing the need for MHC co-stimulation.

Download this eBook from The Scientist and PHC Corporation of North America to find out more about:
T-cell receptor-mediated cancer cell killing
Constructing CAR-T cells
Producing CAR-T cells
Manufacturing CAR-T cells for the clinic

Interested in reading more?

The Scientist ARCHIVES

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?